MTOR and pancreatic neuroendocrine tumor: On the other hand, while dual PI3K and mTOR inhibitor showed improved efficacy in inhibiting tumor growth in preclinical models, adverse effects and poor tolerability were also reported for pancreatic neuroendocrine tumors patients [69–73].